STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Rhea-AI Summary
Gilead Sciences, Inc. is providing $12.6 million in grant funding to 19 organizations through its Setting the P.A.C.E. Initiative to improve the HIV landscape for Black women and girls in the U.S. This initiative aims to increase HIV prevention efforts and health equity for Black cisgender and Transgender women and girls who are disproportionately affected by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
News
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
Rhea-AI Summary
Gilead Sciences, Inc. announces $12.6 million grant funding for 19 organizations to improve HIV landscape for Black women and girls in the U.S. as part of Setting the P.A.C.E. initiative. The grants aim to increase HIV prevention, anti-stigma efforts, and health equity for Black cisgender and Transgender women and girls disproportionately impacted by the HIV epidemic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
Rhea-AI Summary
Gilead Sciences, Inc. announces FDA approval for Biktarvy to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Biktarvy is now the first and only INSTI-based single-tablet regimen approved for this specific group, providing a high barrier to resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
fda approval
News
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Rhea-AI Summary
Gilead Sciences, Inc. announces new clinical data and real-world evidence at CROI 2024, showcasing commitment to advancing antiviral research. Studies cover HIV treatment, COVID-19 impact, and Hepcludex safety in HIV/HBV/HDV coinfection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
-
News
Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change
Rhea-AI Summary
National Black HIV/AIDS Awareness Day's theme 'Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities' highlighted by Gilead grantee, the National Black Leadership Commission on Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
News
Gilead Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Gilead Sciences, Inc. (GILD) executives will be speaking at various investor conferences in March. The conferences include TD Cowen Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Annual Global Healthcare Conference. The webcasts can be accessed on the company's investors page with replays available for 30 days post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
News
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Rhea-AI Summary
Gilead Sciences, Inc. has been named one of America's Most JUST Companies, ranking fifth in the Pharmaceuticals and Biotech industry. The company's commitment to stakeholder engagement, sustainability, and creating a healthier world has been recognized. Gilead's ESG strategy focuses on health equity, access to medicines, inclusive workplace, and environmental sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces promising results of opaganib in treating radiation-induced lung inflammation and fibrosis. Opaganib, a selective SPHK2 inhibitor, significantly improved long-term survival in an in vivo mouse model post ionizing radiation exposure. The data suggest its potential as a medical countermeasure for radiation and cancer therapy. Opaganib is being evaluated for Acute Radiation Syndrome (ARS) and other indications like COVID-19, ARDS, filoviruses, and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
Rhea-AI Summary
Gilead Sciences' innovative antiviral therapies have revolutionized the treatment of chronic hepatitis C, leading to high cure rates and transforming millions of lives globally. The company's commitment to providing low-cost treatments to vulnerable populations has been instrumental in efforts to eliminate the disease by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none
News
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Rhea-AI Summary
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to add seladelpar, a PPARδ agonist for the treatment of Primary Biliary Cholangitis (PBC), with FDA priority review and anticipated US approval in the third quarter of 2024. Seladelpar Phase 3 data showcases a best-in-disease profile for second-line PBC, expanding Gilead's liver disease portfolio and commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.38%
Tags
acquisition
Stock GILD logo
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

#144 Ranked by Market Cap
#2131 Ranked by Stock Gains
#692 Ranked by Dividends

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.